Radiopharmaceutical developer Medco Research last month fileda new drug application for its ViaScint cardiac imaging agent.ViaScint is designed to predict changes in global ventricularfunction after coronary revascularization in patients
Radiopharmaceutical developer Medco Research last month fileda new drug application for its ViaScint cardiac imaging agent.ViaScint is designed to predict changes in global ventricularfunction after coronary revascularization in patients undergoingcoronary artery bypass grafting (SCAN 1/17/96). Medco Research,of Research Triangle Park, NC, also developed cardiac stress agentAdenoscan, which is marketed by Fujisawa.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.